Tagged with Diabetes,

Pharma The General Manager for Eli Lilly Italy, discusses how the company’s continuous commitment to Italy has benefited the organization, the promise the country holds if certain barriers can be overcome, and how Lilly’s rich pipeline is set to boost growth in new areas over the next few years. We interviewed you during your…

Pharma With a large and growing population, and significant domestic health needs, Lilly Egypt general manager Ozkan Ozdogan sees many opportunities for various stakeholders to serve patients, and is focusing on improving healthcare practitioners’ ability to better train diabetes patients to manage their condition.    After 14 years with Lilly Turkey in…

Pharma Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently being implemented in the regulatory system will have on the industry moving forward.   Dr. Piliounis, to start off, you…

Pharma Chris Juliam, Managing Director for Takeda Italy, shares the strategy the company is pursuing in the country, the effects market-access issues are having on innovators and patients, and what new products the company’s pipeline holds for the future. When we interviewed Takeda in 2009, you were ranked 20th in the…

Pharma Medical Union Pharmaceuticals (MUP) acquired Lilly’s Egyptian human insulin vial manufacturing facility in early 2015. Managing Director Ahmed Kelani discusses the national significance of this acquisition given Egypt’s high prevalence of diabetes, and how the transferred technology will support MUP’s ambition to become a leading pharmaceutical manufacturer in the region.…

Pharma Egypt is at the ‘golden stage’ for investment, claims Boehringer Ingelheim country head Mohamed El-Sahhar, who explains how the company is expanding their organization in Egypt ahead of an expansion into diabetes and oncology.  Egypt’s international image is still heavily influenced by the political instability of 2011 to 2013; what…

Pharma Novasep is the largest contract manufacturer for the pharmaceuticals and fine chemicals industries in France. Michel Spagnol, the company’s chairman and CEO, highlights recent reorganization and “back to basics” strategy based on organic growth improving the product mix and underscoring new investments. What is your perspective regarding the state of…

Pharma In Egypt’s diverse marketplace, Novo Nordisk is bringing care to patients across the country with a range of products ranging from affordable established insulin to their most recent generation of innovative products. At the same time, they are investing in localizing production of insulin in Egypt and encouraging best practices in diabetes…

diabetes

Pharma Winner of the Dutch Prix Corona Gallina in 2011, Prof. Dr. Bart Roep discusses his groundbreaking research into type 1 diabetes; his wishes to deal with the cause rather than the symptoms of this disease and the current research climate in the Netherlands. Introduction to Bart Roep and his current…

Holland In a market under strong pressures to contain costs, launching innovative products in a crowded market can be a challenge. Novo Nordisk GM Sanne Groenemeijer believes his organization’s willingness to try various solutions has helped them to maintain their dominant position as the market leader in diabetes. Since you took…

Roche Miguel Centeno, general manager and head of Roche Diabetes Care in Puerto Rico, highlights the affiliate’s strong manufacturing performance in the area of diabetes care (DC) blood glucose test strips above its competitors.   Can you provide us with an overview of the current state of the medical device and…